Q3 Earnings Forecast for AQST Issued By Leerink Partnrs

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for Aquestive Therapeutics to ($0.14) from a previous forecast of ($0.17).
• Aquestive Therapeutics recently reported its Q2 earnings, achieving an EPS of ($0.14), beating consensus estimates by $0.04, although revenue was below expectations at $10 million.
• The current average analyst rating for Aquestive Therapeutics is "Buy," with a consensus target price of $10.14.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Analysts at Leerink Partnrs boosted their Q3 2025 earnings estimates for shares of Aquestive Therapeutics in a report issued on Tuesday, August 12th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. Leerink Partnrs also issued estimates for Aquestive Therapeutics' Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.54) EPS, FY2027 earnings at ($0.39) EPS and FY2028 earnings at ($0.08) EPS.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million.

Other equities analysts also recently issued research reports about the stock. Oppenheimer began coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $7.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics currently has an average rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Stock Up 1.7%

NASDAQ:AQST traded up $0.07 during trading hours on Friday, reaching $4.18. 1,252,185 shares of the company's stock were exchanged, compared to its average volume of 1,196,080. The firm has a market capitalization of $416.83 million, a price-to-earnings ratio of -5.97 and a beta of 1.99. The company has a 50-day moving average of $3.78 and a 200 day moving average of $3.16. Aquestive Therapeutics has a 1-year low of $2.12 and a 1-year high of $5.80.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company's stock valued at $156,000 after purchasing an additional 2,649 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after purchasing an additional 4,125 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Aquestive Therapeutics by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company's stock valued at $106,000 after purchasing an additional 4,557 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.